Metrics to compare | CU6 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCU6PeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.3x | −2.4x | −0.4x | |
PEG Ratio | 0.16 | −0.04 | 0.00 | |
Price/Book | 4.2x | 3.3x | 2.6x | |
Price / LTM Sales | 74.8x | 6.8x | 3.1x | |
Upside (Analyst Target) | 241.0% | 59.7% | 57.4% | |
Fair Value Upside | Unlock | 17.6% | 7.7% | Unlock |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.